What is the recommended neoadjuvant chemotherapy regimen for operable triple‑negative breast cancer?

Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

For stage II-III triple-negative breast cancer, the standard of care is pembrolizumab combined with carboplatin + paclitaxel followed by cyclophosphamide + doxorubicin or epirubicin, with continuation of pembrolizumab in the adjuvant setting (KEYNOTE-522 regimen). 1

Treatment Algorithm by Stage

Stage II-III Disease (Preferred Regimen - Category 1)

The KEYNOTE-522 regimen is the gold standard 1, 2:

Neoadjuvant Phase:

• Pembrolizumab + carboplatin + paclitaxel (typically 12 weeks)
• Followed by pembrolizumab + cyclophosphamide + doxorubicin or epirubicin (typically 8-12 weeks)

Adjuvant Phase:

• Continue pembrolizumab regardless of pathologic response
• The benefit is independent of PD-L1 status 2

This regimen achieves pathologic complete response (pCR) rates of approximately 65% compared to 51% with chemotherapy alone 1. Network meta-analysis confirms this combination (paclitaxel-anthracycline-based + carboplatin + pembrolizumab + cyclophosphamide) has an odds ratio of 3.04 for achieving pCR compared to standard chemotherapy 3.

Stage I Disease (T1c)

For early-stage disease, the approach differs:

• AC (doxorubicin/cyclophosphamide) followed by paclitaxel (dose-dense every 2 weeks or weekly paclitaxel) 1
• TC (docetaxel/cyclophosphamide) is an alternative 1
• For cT2N0 disease, consider adding pembrolizumab 2

Alternative Anthracycline-Free Option (Useful in Certain Circumstances)

Docetaxel + carboplatin + pembrolizumab for 6 cycles 1:

• The NeoPACT study showed 58% pCR rate (65% in node-negative, 45% in node-positive patients)
• 3-year event-free survival of 86%
• Better tolerated with only 3.5% grade ≥3 immune-related adverse events
• Critical caveat: This should NOT routinely substitute for KEYNOTE-522, particularly in node-positive disease where anthracycline-containing regimens remain more effective 1
• Reserve for patients with contraindications to anthracyclines (cardiac concerns, prior anthracycline exposure)

Key Evidence Considerations

Platinum is Essential: Multiple network meta-analyses confirm that platinum-containing regimens significantly improve pCR rates 3, 4, 5. The benefit is independent of germline BRCA1/2 status 2.

Anthracycline Role: While traditional anthracycline-taxane backbones remain standard for stage I disease, the incremental benefit of anthracyclines when combined with pembrolizumab and platinum is less clear 5. However, the KEYNOTE-522 regimen includes anthracyclines and has the strongest survival data.

Dose-Dense vs. Standard Scheduling: For pembrolizumab-based regimens, there is no consensus on dose-dense (every 2 weeks) versus standard (every 3 weeks) anthracycline scheduling due to lack of safety/efficacy data in this context 2. The panel was split 30% supporting dose-dense versus 38% preferring standard scheduling.

Common Pitfalls to Avoid

1. Do not omit pembrolizumab in stage II-III disease - The survival benefit is substantial and independent of PD-L1 status
2. Do not use anthracycline-free regimens routinely in node-positive disease - Reserve for specific contraindications
3. Do not skip adjuvant pembrolizumab even if pCR is achieved - Continue for the full planned duration
4. Do not substitute carboplatin with other platinum agents in the KEYNOTE-522 regimen without evidence

Toxicity Considerations

Platinum-containing regimens increase risk of:

• Febrile neutropenia 4, 5
• Grade 3-4 thrombocytopenia 4, 5
• Gastrointestinal toxicity when combined with anthracyclines and bevacizumab 5

The anthracycline-free docetaxel-carboplatin regimen shows fewer grade ≥3 adverse events compared to anthracycline-taxane combinations 4, making it preferable when cardiac safety is paramount.

Post-Neoadjuvant Management

If residual disease remains after neoadjuvant therapy with taxane, alkylator, and anthracycline-based chemotherapy:

• Capecitabine in the adjuvant setting 1
• For germline BRCA1/2 mutations: Olaparib 1